Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C
July 22, 2014 – Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. (otcqb:NTRP) has signed a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to utilize its proprietary information and data package for the use …
Future of health: LifeMap grabs $5M, partners with Mount Sinai School of Medicine on big data-powered mobile health platform
For better or for worse, we’re living in an era of near constant self-quantification. From wi-fi enabled bathroom scales, to activity monitoring wristbands, to personal DNA sequencing, consumers are gathering more data about their health and wellness than at any time in …
Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease
SPRING HOUSE, Pa., May 5, 2014 /PRNewswire/ — Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC), Prometheus Laboratories Inc. (Prometheus), Mayo Clinic, Rochester, Minnesota (Mayo Clinic), Centre Hospitalier Regional Universitaire …
Auven Therapeutics and BELLUS Health Announce License Agreement with Mount Sinai for KIACTA in Sarcoidosis
May 2, 2014 – Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced that Auven has entered into a license …
Technology Transfer: Commercialization and Innovation Infographic
by AvalancheInfographics. Explore more visuals like this one on the web’s largest information design community – Visually. …
Intranasal Ketamine Confers Rapid Antidepressant Effect in Depression
April 8, 2014 – A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect –within 24 hours—and was well tolerated in patients with treatment-resistant major …
Harrington Scholar-Innovator Grant Program
The Harrington Scholar-Innovator Award recognizes physician-scientists throughout the U.S. whose research has the potential to change standard of care. The Award provides clinical research funding as well as non-financial support to selected investigators and their institutions to help bridge the gap between …
Erik Lium, PhD, Named Vice President of Mount Sinai Innovation Partners
March 31, 2014 – Erik Lium, PhD, a 16-year veteran with an extensive background in the academic, technology and medical sectors, has been named Vice President and Executive Director of Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai …
Harlem Biospace – Biotech Venture Summer Associate
Harlem Biospace(Hb) is a biotech incubator for New York City offering affordable shared wet-lab space for early-stage biotech companies. We have built a centrally located lab outfitted with modern biotech equipment, host unique classes and events, and provide business support – creating …
DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease
February 18, 2014– DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and the Icahn School of Medicine at Mount Sinai announced today that they entered into a research collaboration agreement to investigate the …